Physician profile
Jason Ellen
NPI 1962405928
$10,857.06
in general payments reported to CMS, 2019-2025
25 companies · $2,521 in 2025
The $2,521 reported for 2025 was more than what 98% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,889 · 2020: $724 · 2021: $1,183 · 2022: $681 · 2023: $1,145 · 2024: $2,714 · 2025: $2,521.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,355 · Honoraria: $25.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,354.70 |
| Honoraria | $25.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $2,111.81 | 2019-2025 | |
| Alcon Vision LLC | $1,015.20 | 2019-2025 | Clareon, Clareon Panoptix Pro, Argos |
| Aerie Pharmaceuticals, INC. | $781.13 | 2019-2021 | |
| Tarsus Pharmaceuticals, INC. | $717.60 | 2024-2025 | Xdemvy |
| Johnson & Johnson Surgical Vision, INC. | $638.95 | 2019-2025 | Tecnis Iol, Tecnis Iol, Catalys System |
| Rxsight INC | $607.65 | 2022-2025 | Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd), Rxsight Contact Lens |
| Abbvie INC. | $544.90 | 2022-2025 | |
| Allergan, INC. | $519.23 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $502.27 | 2022-2024 | Miebo, Envista Mx60 Iol, Xiidra |
| Sun Pharmaceutical Industries INC. | $490.11 | 2019-2025 | Cequa, Xelpros |
| Sight Sciences, INC. | $438.86 | 2019-2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $350.95 | 2019-2021 | |
| Amgen INC. | $350.67 | 2024-2025 | Tepezza |
| Dompe US, INC. | $342.40 | 2021-2025 | Oxervate |
| Glaukos Corporation | $317.99 | 2019-2025 | Photrexa Viscous and Photrexa, Idose |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| The Cameron-Ehlen Group, INC. | $266.27 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $214.57 | 2019-2023 | |
| New World Medical,INC. | $159.83 | 2022-2023 | |
| Shire North American Group INC | $138.94 | 2019 | |
| Kala Pharmaceuticals, INC. | $111.01 | 2019-2022 | |
| Horizon Therapeutics Plc | $88.76 | 2022-2023 | Tepezza |
| Ocular Therapeutix, INC. | $68.51 | 2025 | Dextenza |
| Carl Zeiss Meditec Ag | $38.80 | 2020 | |
| Harrow Eye, LLC | $21.25 | 2024 | Vevye |
| Astellas Pharma US INC | $19.40 | 2025 | Izervay |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Ellen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.